HELIA Biomonitoring’s mission is to enable continuous monitoring of therapeutic drug concentrations, organ function markers, and treatment response markers for personalized patient care.

Liver toxicity is the main safety reason for drug attrition in clinical trials, causing 1 in every 13 drugs to fail. We have developed a novel, human liver model in a dish called hello which accurately predicts the toxicity of drugs.

A medical device for standardised capillary blood sampling without trained personnel, integrated into routine hospital and laboratory workflows.

At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.

Basal cell carcinoma is the most diagnosed cancer worldwide. IMcoMET is developing a novel treatment method that will lead to removal of lesions with only minor side effects.

Immunara is designing nanobody-based carriers that bind to CD169 and deliver a variety of antigen formats, such as recombinant proteins, peptides, viral vectors or RNA.

At IMPACT, they create a therapy that combines patient-derived chondrons with off-the-shelf allogeneic mesenchymal stromal cells (MSCs), enabling regenerative treatment in a single surgery. This reduces both patient burden and hospital costs compared to current cell therapies.

Injectable bone filler with drug release function for treatment of bone infections (INBORN)

Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.

Liquid biopsy platform for purification and collection of intact CTCs directly from blood